Wills Eye Institute Retina Service, Mid Atlantic Retina, Philadelphia, PA 19107, USA.
JAMA Ophthalmol. 2013 Mar;131(3):365-9. doi: 10.1001/jamaophthalmol.2013.642.
To evaluate the effects of high-dose oral omega-3 fatty acid supplementation on electroretinography and omega-3 index in patients with dry age-related macular degeneration.
Single institution, prospective, nonrandomized, noncomparative interventional case series comprising 34 eyes of 17 patients older than 50 years of age with early to intermediate age-related macular degeneration. Patients received oral supplementation with 4 g of omega-3 fatty acids daily (840 mg eicosapentaenoic acid/2520 mg docosahexaenoic acid) for 6 months. The main outcome measures included Early Treatment Diabetic Retinopathy Study best-corrected visual acuity, change in N1 and P1 peak amplitudes on multifocal electroretinographic testing, and change in serum omega-3 index.
Mean baseline Early Treatment Diabetic Retinopathy Study best-corrected visual acuity letter score was 77 letters (Snellen equivalent of 20/32). There were no statistically significant changes in visual acuity (P = .12) or retinal function by multifocal electroretinographic testing. Serum omega-3 index increased by an average of 7.6% during the course of the study (P < .001). Study limitations included the relatively short duration of the study and small number of participants.
Short-term supplementation with high doses of omega-3 fatty acids does not result in any measurable changes in visual acuity or retinal function by multifocal electroretinographic testing. Dietary supplementation with 4 g of omega-3 fatty acids results in a significant increase in serum omega-3 index in patients with dry age-related macular degeneration and may provide a useful clinical measure for future studies.
clinicaltrials.gov Identifier: NCT01258335.
评估大剂量口服欧米伽-3 脂肪酸补充剂对干性年龄相关性黄斑变性患者的视网膜电图和欧米伽-3 指数的影响。
单机构、前瞻性、非随机、非对照的干预性病例系列研究，纳入 17 名年龄大于 50 岁的早期至中期年龄相关性黄斑变性患者的 34 只眼。患者接受每日 4 克欧米伽-3 脂肪酸（840 毫克二十碳五烯酸/2520 毫克二十二碳六烯酸）口服补充，持续 6 个月。主要观察指标包括早期治疗糖尿病视网膜病变研究最佳矫正视力、多焦视网膜电图检查 N1 和 P1 波峰振幅的变化以及血清欧米伽-3 指数的变化。
平均基线早期治疗糖尿病视网膜病变研究最佳矫正视力字母评分（Snellen 视力表等价物）为 77 个字母（20/32）。视力（P =.12）或多焦视网膜电图检查的视网膜功能均无统计学显著变化。在研究过程中，血清欧米伽-3 指数平均增加了 7.6%（P <.001）。研究局限性包括研究持续时间相对较短且参与者数量较少。
短期补充大剂量欧米伽-3 脂肪酸不会导致多焦视网膜电图检查的视力或视网膜功能出现任何可测量的变化。在干性年龄相关性黄斑变性患者中，每日补充 4 克欧米伽-3 脂肪酸可显著增加血清欧米伽-3 指数，可能为未来的研究提供一种有用的临床指标。
clinicaltrials.gov 标识符：NCT01258335。
